TCRX
TCRX clinical trials: TScan Therapeutics, Inc.
Every trial on ClinicalTrials.gov where TScan Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
TCRX on the catalyst calendar · TCRX registry changes
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07702578A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationTScan Therapeutics, Inc. · AMLActive, not recruitingTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026ActualPhase 1NCT05473910A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)TScan Therapeutics, Inc. · AMLActive, not recruitingTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 10, 2026ActualNo phase registeredNCT06587828A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseTScan Therapeutics, Inc. · Autoimmune DiseasesCompletedTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2024ActualNo phase registeredNCT05230186A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.TScan Therapeutics, Inc. · Solid Tumor, AdultCompletedTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 1NCT05973487A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsTScan Therapeutics, Inc. · Head and Neck CancerActive, not recruitingTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2026Sponsor estimateNo phase registeredNCT05812027A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsTScan Therapeutics, Inc. · Head and Neck CancerActive, not recruitingTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2040Sponsor estimateNo phase registeredNCT06976736A Long Term Follow-up Study of TScan TCR-T ProductsTScan Therapeutics, Inc. · AMLRecruitingTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 4, 2021ActualNo phase registeredNCT04680416Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint InhibitorsTScan Therapeutics, Inc. · Renal Clear Cell CarcinomaWithdrawnTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 12, 2021ActualNo phase registeredNCT04397900Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral EpitopesTScan Therapeutics, Inc. · Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 InfectionCompletedTCRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner